Shareholders Equity: The sum of preferred and common equity items.
Silexion Therapeutics Corp (SLXN) had Shareholders Equity of $2.59M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-1.74M |
|
-- |
|
-- |
|
$1.65M |
|
$-1.65M |
|
$-0.09M |
|
$-1.74M |
|
$-1.74M |
|
$-1.74M |
|
$-1.74M |
|
$-1.74M |
|
$-1.74M |
|
$-1.65M |
|
$-1.65M |
|
6.78M |
|
6.78M |
|
$-0.26 |
|
$-0.26 |
|
| Balance Sheet Financials | |
$7.72M |
|
$0.03M |
|
$0.59M |
|
$8.31M |
|
$2.40M |
|
$2.99M |
|
$3.33M |
|
$5.72M |
|
$2.59M |
|
$2.59M |
|
|
Shareholders Equity |
$2.59M |
8.69M |
|
| Cash Flow Statement Financials | |
$-2.45M |
|
$-0.01M |
|
$7.43M |
|
$1.27M |
|
$6.23M |
|
$4.96M |
|
$0.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.22 |
|
-- |
|
-- |
|
0.54 |
|
1.16 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.46M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-67.09% |
|
-67.09% |
|
-20.88% |
|
-31.10% |
|
$0.30 |
|
$-0.36 |
|
$-0.36 |
|